Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

European Urology

Volumn 71, Issue 2, 2017, Pages 204-209

  Wells, J Connor ^a,b   Stukalin, Igor ^a   Norton, Craig ^c   Srinivas, Sandy ^d   Lee, Jae Lyun ^e   Donskov, Frede ^f   Bjarnason, Georg A ^g   Yamamoto, Haru ^h   Beuselinck, Benoit ⁱ   Rini, Brian I ^j   Knox, Jennifer J ^k   Agarwal, Neeraj ^l   Ernst, D Scott ^m   Pal, Sumanta K ⁿ   Wood, Lori A ^o   Bamias, Aristotelis ^p   Alva, Ajjai S ^q   Kanesvaran, Ravindran ^r   Choueiri, Toni K ^c   Heng, Daniel Y C ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Ulsan College of Medicine   (South Korea)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j TAUSSIG CANCER INSTITUTE   (United States)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l UNIVERSITY OF UTAH   (United States)

^m LONDON REGIONAL CANCER PROGRAM   (Canada)

ⁿ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^o QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^p UNIVERSITY OF ATHENS   (Greece)

^q UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^r DIVISION OF MEDICAL ONCOLOGY   (Singapore)

more..

Author keywords

Metastatic renal cell carcinoma; Targeted therapy; Third line therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; CLINICAL TRIAL; FACTUAL DATABASE; INTERNATIONAL COOPERATION; KIDNEY TUMOR; MORTALITY; MULTICENTER STUDY; RENAL CELL CARCINOMA; SECONDARY; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DATABASES, FACTUAL; FEMALE; HUMANS; INTERNATIONALITY; KIDNEY NEOPLASMS; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 85006351502     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.05.049     Document Type: Article

References (21)

1. [1] Escudier, B., Szczylik, C., Porta, C., Gore, M., Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 9 (2012), 327–337.
2. [2] Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New Engl J Med 373 (2015), 1803–1813.
3. [3] Choueiri, T.K., Escudier, B., Powles, T., et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. New Engl J Med 373 (2015), 1814–1823.
4. [4] Calvo, E., Grunwald, V., Bellmunt, J., Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. Eur J Cancer 50 (2014), 1321–1329.
5. [5] Ko, J.J., Choueiri, T.K., Rini, B.I., et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 110 (2014), 1917–1922.
6. [6] Motzer, R.J., Escudier, B., Oudard, S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116 (2010), 4256–4265.
7. [7] Motzer, R.J., Escudier, B., Oudard, S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008), 449–456.
8. [8] Motzer, R.J., Porta, C., Vogelzang, N.J., et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomized phase 3 trial. Lancet Oncol 15 (2014), 286–296.
9. [9] Motzer, R.J., Jonasch, E., Agarwal, N., et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw 13 (2015), 151–159.
10. [10] Escudier, B., Porta, C., Schmidinger, M., et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:Suppl 3 (2014), iii49–iii56.
11. [11] Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
12. [12] Heng, D.Y., Xie, W., Regan, M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27 (2009), 5794–5799.
13. [13] Alimohamed, N., Lee, J.L., Srinivas, S., et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 12 (2014), e127–e131.
14. [14] Jonasch, E., Signorovitch, J.E., Lin, P.L., et al. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Curr Med Res Opin 30 (2014), 2041–2050.
15. [15] Iacovelli, R., Carteni, G., Sternberg, C.N., et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer 49 (2013), 2134–2142.
16. [16] Geynisman, D.M., Hu, J.C., Liu, L., Tina Shih, Y.C., Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer 13 (2015), e93–e100.
17. [17] Pal, S.K., Malangone, E., Bhurke, S., et al. Real-world treatment patterns in third-line patients with metastatic renal cell carcinoma (mRCC): The changing landscape in the United States. J Clin Oncol, 31(Suppl 6), 2013 Abstract 390.
18. [18] Jones, R., DeSantis, M., Access to targeted therapies in renal cell cancer. Semin Oncol 40 (2013), 521–528.
19. [19] Calvo, E., Escudier, B., Motzer, R.J., et al. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48 (2012), 333–339.
20. [20] Ko, J.J., Xie, W., Kroeger, N., et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16 (2015), 293–300.
21. [21] Soerensen, A.V., Donskov, F., Hermann, G.G., et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2. Eur J Cancer 50 (2014), 553–562.